Trial Profile
A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 May 2014
Price :
$35
*
At a glance
- Drugs LMB 9 (Primary)
- Indications Colon cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2007 New trial record.